KRAS, NRAS, and BRAF mutation prevalence, clinicopathological association, and their application in a predictive model in Mexican patients with metastatic colorectal cancer: A retrospective cohort study.
Mutations in KRAS, NRAS, and BRAF (RAS/BRAF) genes are the main predictive biomarkers for the response to anti-EGFR monoclonal antibodies (MAbs) targeted therapy in metastatic colorectal cancer (mCRC). This retrospective study aimed to report the mutational status prevalence of these genes, explore...
Main Authors: | Hector Eduardo Sanchez-Ibarra, Xianli Jiang, Elena Yareli Gallegos-Gonzalez, Adriana Carolina Cavazos-González, Yenho Chen, Faruck Morcos, Hugo Alberto Barrera-Saldaña |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0235490 |
Similar Items
-
KRAS, NRAS, and BRAF Mutation Pattern in Metastatic Colorectal Cancer: A Study from Northwest Iran
by: Roya Dolatkhah, et al.
Published: (2019-08-01) -
KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer – practical implications for the clinician
by: Afrăsânie Vlad-Adrian, et al.
Published: (2019-09-01) -
KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
by: Sergiu Pasca, et al.
Published: (2019-10-01) -
Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer.
by: Claire Franczak, et al.
Published: (2020-01-01) -
Mutational analysis of KRAS and NRAS in metastatic colorectal cancer
by: Romina Oliveira Silva
Published: (2019)